Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Raltegravir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms RASSTER
- 17 Dec 2013 Planned end date changed from 1 May 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 19 Oct 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-003298-26).
- 06 Feb 2012 Actual initiation date (1 Jan 2012) added as reported by ClinicalTrials.gov.